Leerink initiated coverage of Cartesian with an Outperform rating and $39 price target. The firm believes Cartesian’s differentiated mRNA CAR T approach and encouraging early results from Descartes-08 in MG have placed the company in a unique and competitive position in the emerging cell therapy landscape for autoimmune diseases. Leerink also believes Descartes-08’s advantageous attributes may expand the access for CAR-T cell therapy to a broader group of patients with autoimmunity, and anticipates that Cartesian’s competitive position will be strategically attractive to large pharma/biotech companies looking for entry points into this next wave of therapies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics: Capital Structure Updates and Conference Insights
- Selecta Biosciences Inc trading halted, news pending
- Cartesian announces new employment inducement grants
- Cartesian Therapeutics Bolsters Executive Team with Key Appointments
- Cartesian Therapeutics’ Strategic Stock Reorganization Wins Approval